Introduction
The biological functions of human immunodeficiency virus type 1 (HIV-1) env glycoprotein glycans remain elusive although there is evidence to indicate that glycans are likely to play a major role in the HIV-I life cycle: (i) carbohydrate moieties represent 50 ~ of outer membrane glycoprotein (gp 120) M~ (Matthews et al., 1987; Fenouillet et al., 1989 Fenouillet et al., , 1990 ), (ii) N-glycosylation sites of the precursor gpl60 sequence are highly conserved among the different primate immunodeficiency viruses (Alizon et al., 1986; Chakrabarti et al., 1987) and (iii) the carbohydrate composition of recombinant gpl20 (rgpl20) produced in different mammalian cell lines and of viral gpl20 (vgpl20) is similar (Geyer et al., 1988; Mizuochi et al., 1988; Fenouillet et al., 1989) .
It is mostly the possible role of glycans in the interaction of HIV-1 with target cells, namely the binding of gpl20 to the CD4 cell membrane receptor, the gp41mediated fusion of the virus envelope and cell membrane, or synctium formation (McCune et al., 1989; Freed et al., 1990; Klatzmann et al., 1990) , that has been investigated so far. The results have been conflicting (Lifson et al., 1986; Gruters et al., 1987; Matthews et al., 1987; Robinson et al., 1987; Karpas et al., 1988; Montefiori et al., 1988; Fennie & Lasky, 1989; Fenouillet et al., 1989; Hansen et al., 1989; Kozarsky et al., 1989; Pal et al., 1989a) . For example, different lectins can block HIV-1 infection in vitro (Lifson et al., 1986; Robinson et al., 1987; Hansen et al., 1989) , but this simply results from steric hindrance (Anderson et al., 1991 ;  L. Gattegno, A. Ramdani, T. Jouault, L. Saffar & J. C. Gluckman, unpublished results). Our own findings indicate that enzymic removal of glycans from mature rgp 160 or rgp 120, or from vgp 120, does not significantly reduce the ability to bind to CD4 presented either in soluble form or at the cell membrane (Fenouillet et al., 1989 (Fenouillet et al., , 1990 . Moreover, when envelope glycoproteins of virions are completely deglycosylated, HIV-1 still binds to CD4 ÷ cells with an affinity sufficient to result in infection, indicating that glycans of mature gpl20/gp41 play but a limited role in HIV infectivity (FenouiUet et al., 1990) . In contrast, Gruters et al. (1987) and others (Robinson et al., 1987; Karpas et al., 1988 ; 0001-0261 © 1991 SGM E. Fenouillet and J.-C. Gluckman al., 1988; Kozarsky et al., 1989; Pal et al., 1989a) have demonstrated that sugar analogues which inhibit the processing of carbohydrate chains by interfering with the action of glucosidases or mannosidase I markedly reduce virus infectivity and syncytium formation. The apparent discrepancy between the latter and our results may be explained by the hypothesis that, after translation, glycans present on the mature envelope glycoproteins are not of paramount importance for HIV-1 infectivity, whereas abnormal glycosylation can affect the cellular routing, processing and folding of the glycoproteins, resulting in altered bioactivity.
As glycosylation is important for the bioactivity and/or immunoreactivity of glycoproteins (Olden et al., 1985; Fenouillet et al., 1986; Davis et al., 1990) and to test this hypothesis, we have compared the bioactivity and conformation of normal and glycosylation inhibitortreated rgpl60, as assessed respectively by its binding to CD4 and its immunoreactivity. We have used 1deoxynojirimycin (dNM) (Elbein, 1987) , a glucose analogue that inhibits by approximately 50 to 75% the removal of glucose residues from Glc3Man9GlcNAc2 moieties (Glc, glucose; Man, mannose; GlcNAc, Nacetyl glucosamine) by ~-glucosidases in the rough endoplasmic reticulum (RER) just after transfer of this glycan precursor to the nascent protein backbone (Kornfeld & Kornfeld, 1985) . Thus, rgpl60 produced in d N M-treated cells comprises a high number of mannosylated Glc3Man9GlcNAc 2 species that cannot be further modified by glycosidases and glycosyltransferases, hence its aberrant glycosylation pattern.
Methods
Production of recombinant envelope glycoproteins. Cells of the BHK-21 line were cultured at 37 °C in a humidified atmosphere of 5% CO2 in Glasgow medium (Gibco-BRL) with 5% foetal calf serum (FCS) in the presence of absence of 2 or 4 mM-dNM (a gift of R. Gruters and H. Ploegh, Red Cross Blood Transfusion Service, University of Amsterdam, The Netherlands). The culture was followed for 3 weeks to observe possible effects of dNM on cell viability and growth; cells were then infected with either a control or a recombinant vaccinia virus (0-1 TCIDs0/cell) as described by Kieny et al. (1988) . In the thymidine kinase gene of the latter the env coding sequence of HIV-1 LAV-BRU was inserted. This had been modified by site-directed mutagenesis to destroy the gp120-gp41 cleavage site and to remove the anchor domain of gp41 (Kieny et al., 1988) . Soluble rgpl60 was readily released from the cell membrane into the medium. After 3 days, cell pellets were lysed with PBS, 2 ~ Tween 20, and the supernatant was concentrated 20-fold using a 30K cut-off Centriprep (Amicon).
Mosquito cells were cultured in Grace's medium with 10% FCS. Cells were infected for 3 days with Autographa californica polyhedrosis virus with the same env gpl60 sequence construct (Kieny et al., 1988) (2 TCIDs0/cell). Soluble baculovirus-expressed rgpl60 was then recovered.
Soluble recombinant gpl20 obtained from Escherichia coli (a gift from I. Jones, NERC Institute of Virology, Oxford, U.K.) was prepared as described by Morikawa et al. (1990a) .
Quantification of recombinant glycoproteins. The amount of rgp 160 or rgp 120 obtained in the different systems was measured as follows. Five, 2.5 and 1 ~tl of the different concentrates were blotted on a nitrocellulose filter and adjusted to the same 10 ~tl final volume of PBS, pH 7.4. After saturation, the nitrocellulose filter was incubated at 20 °C for 2 h with a 100-fold dilution of human serum from an HIVseropositive individual devoid of antibodies against vaccinia virus or, in some experiments, of the murine monoclonal antibody (MAb) 110-4 (Genetic Systems). After three washes with PBS, pH 7.4, 0.5% casein, 0.5~ Tween 20, peroxidase-labelled anti-mouse or anti-human IgG antibodies (Amersham) were added at 1:25. After 2 h at 20 °C and three more washes, staining was performed using diaminobenzidine in PBS with 1% H202. The results obtained with the different volumes of sample tested were compared with those obtained with a known reference rgpl60 (batch ICC14; Pasteur-Merieux Vaccins et Serums, Marnes-la-Coquette, France).
Carbohydrate composition of the glycoproteins. Envelope glycoproteins were treated with endoglycosidases from Boehringer-Mannheim as previously described (Fenouillet et al., 1989 (Fenouillet et al., , 1990 . Briefly, 2 ~tg of rgpl60 was mixed for 24 h at 37 °C with 500 milliunits (mU) of endoglycosidase F-N-glycanase mixture (Endo FNG) which cleaves all glycan moieties, or with 500 mU of N-glycanase-free endoglycosidase F (Endo F) which cleaves high-mannose and non-fucosylated biantennary chains, or with 5 mU of endoglycosidase H (Endo H) which cleaves high-mannose structures (Tarentino et al., 1989) . No proteolysis was observed. Control rgpl60 was mock-treated in the same manner. The bacterial rgpl20 was treated with Endo FNG only.
SDS PAGE and Western blotting were performed as described by Fenouillet et aL (1990) , using serum from an HIV-l-seropositive patient devoid of antibodies against vaccinia virus.
Flow cytometry analysis. Increasing amounts of the different glycoprotein samples were incubated with 5 × 105 cells of the CEM 13 subclone (Fenouillet et al., 1989 (Fenouillet et al., , 1990 in 100 ~tl of PBS, 0.5% bovine serum albumin (BSA), 0.05% NaN 3 for 2 h at 20 °C. This temperature allowed glycoprotein binding to the cells but prevented endoglycosidase activity when the enzymes were used (as discussed by Fenouillet et al., 1990) . Staining was performed with a pool of polyclonal purified human anti-HIV-1 IgG from different patients and sheep anti-human IgG antibodies. Membrane fluorescence was measured using a fluorescence-activated cell sorter analyser (Becton-Dickinson).
Anti-CD4 MAb Leu3a, which interferes with the binding of rgp 160 to CD4 (Klatzmann et al., 1990) , was used as a specificity control for the binding of rgpl60 to CEM cells; the cells were preincubated for 5 min at 37 °C with 500 ng of Leu3a before addition of a suboptimal rgpl60 concentration (30 ng).
lmmunoreactivity of gpl60
(i) EL1SA. Microwell plates (Polysorb; Nunc) were coated with 100 Ixl of MAb 110-4 diluted 1 : 100 in PBS. After 2 h at 20 °C, the plates were washed with PBS, 0.05% Tween, and increasing amounts of concentrated env glycoproteins diluted in PBS were added and incubated overnight at 4°C. Endo FNG-deglycosylated rgpl60 samples were also examined. After three washes with PBS, 0-05% Tween, purified polyclonal human anti-HIV-1 IgG were added. After 2 h at 4 °C and three washes, peroxidase-labelled anti-human IgG antibodies (1:300 dilution; Amersham) were added for 2 h at 4 °C. After four washes, substrate was added and absorbance at 450 nm was measured after 30 min.
(ii) Immunoaffinitypurification. One mg of MAb 110-4 was incubated overnight at 4°C with 1 g of activated CNBr-Sepharose CL4B (Pharmacia) following the manufacturer's instructions. One ~tg of rgpl60 obtained from cells with or without dNM treatment was added for 10 h at 4 °C, as described by Fenouillet et aL (1989) . After washing, bound glycoproteins were eluted using 0.5M-formic acid, 150mM-NaCI, and the pH was immediately raised to 7 using ammonium acetate (FenouiUet et al., 1990) . After lyophilization, 10 ktl H20 was added, and dot blot quantification of the glycoprotein present in the different eluates was performed with the anti-HIV-1 polyclonal human IgG or with MAb 110-4, revealed with appropriate anti-IgG antibodies. Results were compared with those of a standard curve obtained with the known reference rgpl60 from batch ICC14.
Results

Characterization of rgp l 60 produced by d N M-treated cells (d+rgpl60)
Concentrations of rgpl60 from d N M -t r e a t e d cells (d+rgp 160) and of rgp 160 from untreated cells (d-rgp 160) were measured by a dot blot assay using a polyclonal anti-HIV h u m a n serum ( Fig. l a) . The amounts of d+rgpl60 and d -r g p l 6 0 ( Fig. lb ) present in the concentrated supernatant were the same, 10 ng/~tl approximately, as was the concentration of baculovirus rgpl60 ( Fig. 1 c) ; bacterial rgpl20 ( Fig. 1 c) was twice as concentrated; d-rgp 160 and d+rgp 160 also exhibited a similar immunoreactivity in dot blot assays using either M A b 110-4 as antibody ( Fig. l d) or heat-denatured rgp 160 samples as antigens (data not shown), or in the Western blot (Fig. 2) . No reactivity was noted when, as a control, 5 p.l of vaccinia virus-infected cell supernatant was dotted on nitrocellulose, or when any step of the assay was omitted.
We next examined whether the carbohydrate structure of d+rgpt60 was altered. As expected, d -r g p l 6 0 presented a glycosylation pattern that was identical to that of rgpl60 from reference batch ICC14 when examined by endoglycosidase analysis (Fig. 2a, b ). Approximately 50~o of glycans were removed by Endo H or Endo F, and they were thus high-mannose or biantennary species; the remaining carbohydrates were composed of fucosylated or multiantennary structures that were resistant to these enzymes but sensitive to Endo F N G , which cleaves all glycans from the polypeptide backbone (Tarentino et al., 1989) . The glycosylation pattern of d+rgpl60 ( Fig. 2c ) was different from that of d -r g p l 6 0 : in the absence of endoglycosidase treatment, the band that corresponded to d+rgpl60 was spread between 170K and 140K, which is compatible with a family of molecules having highly heterogeneous glycosylation. The effect of d N M appeared to be incomplete when used at 2 mM (data not shown) as well as at 4 mM in that Endo H and Endo F treatment of d+rgp 160 resulted in a smear corresponding to between 160K and 90K, indicating heterogeneity with respect to sensitivity to the enzymes. However, d+rgp 160 was more susceptible to Endo H and Endo F and, thus, had more high-mannose species than d-rgpl60.
Baculovirus rgp 160, which is known to express glycans of the high-mannose type, had an Mr of 140K. Both Endo H and Endo F treatments resulted only in a reduction to 11 OK, whereas Endo F N G led to a completely deglycosylated molecule of 90K (Fig. 2d ). As expected, nonglycosylated bacterial rgp 120 displayed a 60K band that was not affected by Endo F N G (Fig. 2e ). In line with our previous findings (Fenouillet et al., 1989 (Fenouillet et al., , 1990 , the efficiency of endoglycosidase treatment was independent of the presence of SDS (0.02 ~) and/or Triton X-100 (1 ~) (data not shown). E. Fenouillet and J.-C. Gluckman 
Binding of the different rgpl60 and rgpl20 to the membrane of CD4 + cells
To examine possible modifications of env glycoprotein bioactivity induced by dNM, we compared the ability of the different rgpl60 to bind to the membrane of CD4 ÷ cells using an indirect immunofluorescence assay after labelling with polyvalent human anti-HIV IgG that recognizes d+rgp 160 and d-rgp 160 to the same extent (as proven in a competitive radioimmunoassay using radiolabelled rgpl60 from batch ICC14; data not shown).
Increasing quantities of glycoproteins were added to the cells and the amount that bound to the membrane was measured by determining the mean fluorescence intensity obtained. Under these conditions, adsorption of suboptimal amounts of d-rgp 160 and baculovirus rgp 160 to the cells could be inhibited by Leu3a, which indicated a specific interaction with membrane CD4 (Fig. 3a) .
Both d-rgp160 and baculovirus rgpl60 bound to the membrane of CD4 ÷ cells to the same extent as rgpl60 from batch ICC14, whereas the binding of d+rgpl60 was strongly reduced; bacterial rgpl20 did not bind at all (Fig. 3b ).
Immunoreactivity of d+rgp l60 as compared with d-rgp l 60
Proper processing of carbohydrates may direct the threedimensional structure of glycoproteins and, therefore, influences their conformation and antigenicity (Alexander & Elder, 1984; Olden et al., 1985; Fenouillet et al., 1986; Davis et al., 1990) . Whether this was the case for rgp160 was investigated by two approaches based on the recognition by MAb 110-4 of an epitope (amino acids 308 to 328) in the third variable domain (the V3 loop) of gpl20. This MAb has comparable reactivity to native and enzymically deglycosylated d-rgp 160 (Fenouillet et al., 1989) , as well as to d-rgpl60 and d+rgpl60 blotted on a nitrocellulose filter ( Fig. 4c , row E). First, an ELISA was used, in which rgpl60 was captured by MAb 110-4 and subsequently revealed with the pool of polyclonal human anti-HIV IgG known to recognize d-rgpl60 and d+rgpl60 to the same extent. Both baculovirus rgpl60 and ICC14 rgpl60 were similarly recognized in this test (Fig. 4a ). However, 10fold more d+rgpl60 than d-rgpl60 was required to obtain the same absorbance reading, but only a twofold reduction of immunoreactivity was noted when comparing Endo FNG-deglycosylated d-rgpl60 with its untreated counterpart (Fig. 4a, b) . In contrast, removal of glycans from d+rgpl60 almost completely abolished binding to 110-4 MAb (Fig. 4b) .
In the next series of experiments, 1 ~tg of d+rgpl60 or d-rgpl60 in solution was incubated overnight with 110-4-Sepharose complexes. After elution, bound rgp 160 was blotted onto nitrocellulose, and again reacted with either human anti-HIV IgG, or MAb 110-4, in comparison with different known amounts of gpl60 from batch ICC14 (Fig. 4c, row A) . As controls, it was shown that Endo FNG present in the medium did not influence staining in the test (Fig. 4c, rows D and E) , that supernatant obtained from acid elution of 110-4-Sepharose complexes in the absence of rgpl60 could not be labelled by anti-human or anti-mouse IgG antibodies (Fig. 4c, rows D and E) and, thus, did not contain detectable amounts of MAb 110-4, and that 500 ng of deglycosylated d-rgpl60 or d+rgpl60 directly blotted on the filter were recognized to the same extent by the human or the mouse anti-gp160 antibodies (Fig. 4 c, rows D and E) . Here again, the ratio between soluble d-rgpl60 and d+rgpl60 retained by and eluted from 110-4-Sepharose was in the order of 10 ( Fig. 4c, rows B and d+rgpl60, respectively, eluted from l l0-4-Sepharose (incubated with 1 lag of d-rgpl60 or d+rgpl60 respectively). Positions 1 and 3, undiluted samples; positions 2 and 4, twofold diluted samples untreated (2) or treated (4) with Endo FNG before incubation with Sepharose. Row D. Position 1, eluate from 110-4-Sepharose not preincubated with C). As in the ELISA, Endo FNG-treated d+rgpl60 was not retained by 110-4-Sepharose complexes in contrast to similarly treated d-rgpl60 (Fig. 4c , row C).
Discussion
Our recent results (Fenouillet et al., 1989 (Fenouillet et al., , 1990 indicate that, after translation and protein biosynthesis, carbohydrates present on mature env glycoproteins do not play a major role in HIV-1 infectivity. However, virus infectivity clearly depends on proper processing of carbohydrates of nascent glycoproteins (Gruters et al., 1987; Robinson et al., 1987; Karpas et al., 1988; Montefiori et al., 1988; Pal et al., 1989a) , most probably because at early stages glycosylation can affect the cellular routing, processing and three-dimensional structure of these proteins.
To examine the role which sugar processing plays in the production of infectious HIV-1, we have investigated the modifications to rgpl60 induced by an inhibitor of the biosynthesis and early processing of glycans, dNM. Such post-translational modifications, which occur in the R E R and in the Golgi apparatus, may profoundly affect the proper synthesis, transport and secretion of glycoproteins. For example, the retention of Glc residues disturbs routing in the R E R ; treatment with d N M inhibits formation of Sindbis virus particles from B H K cells (Elbein et al., 1987) ; and improperly glycosylated G protein of vesicular stomatitis virus is inefficiently transported to the plasma membrane (Gibson et al., 198l) . With respect to H I V -I , virion formation is not affected by glucose trimming inhibitors such as d N M or castanospermine, as demonstrated by Gruters et al. (1987; and personal communication) and other authors (Karpas et al., 1988; Montefiori et al., 1988; Pal et al., 1989a) , although these compounds as well as tunicamycin (which inhibits the biosynthesis of glycan precursor) or 1-deoxymannoj irimycin (an inhibitor of mannosidase I) impair HIV-1 infectivity. Drugs that act on enzymes involved in later stages of the carbohydrate processing pathway have no observed effect (Gruters et al., 1987; Karpas et al., 1988; Montefiori et al., 1988) .
Inhibition by d N M appears partial even at high concentrations such as 2 or 4 mM. This may explain the rgpl60; position 2, anti-HIV IgG missing (500 ng d-rgpl60 coated); positions 3 and 4, direct blotting of Endo FNG-treated d+rgpl60 (500 rig) and Endo FN G-treated d-rgp 160 (500 ng). Row E. Labelling with MAb 110-4. Position 1, eluate from ll0-4-Sepharose not preincubated with rgp160; position 2, MAb 110-4 missing (500 ng d-rgpl60 coated); positions 3 to 5, 1000 ng, 500 ng and 250 ng of rgpl60 from batch ICC14; positions 6 and 7, direct blotting of Endo FNG-treated d+rgpl60 (500ng) and Endo FNG-treated d-rgpl60 (500 ng). low drug toxicity that is usually observed for cells, because only glycoproteins expressing a high number of glycans and/or the glycans of which are involved in folding are potentially affected by dNM treatment. But as rgpl60 contains more than 30 glycosylation sites (Geyer et al., 1988; Mizuochi et al., 1988; Fenouillet et al., 1989) , the incomplete inhibition of a-glucosidases caused by dNM may still result in a sufficient number of aberrantly glycosylated glycans to lead to improper folding and perturb the bioactivity of the molecule. Under these conditions, dNM could be considered to be a rather specific potential antiviral agent. With this possibility in mind, we examined d+rgpl60 produced in high yield from eukaryotic cells using a concentration protocol that avoided any affinity step [antibody (Fenouillet et al., 1990) or lectin] so as to obtain an unselected population of molecules.
Under these conditions, dNM affected neither cell viability nor rgpl60 production, and inhibition of glucose trimming did not alter rgpl60 cell production and secretion (data not shown). However, d+rgpl60 displayed a wider range of Mr than d-rgpl60 in Western blot, an indication of the heterogeneity in glycosylation of the molecules obtained from dNM-treated cells. Also endoglycosidase analysis of d+rgp 160 showed that some species were resistant to Endo H, even when they were more heterogeneous and in less significant amounts than was d-rgpl60. Such resistant species indicate that glycans other than high-mannose chains were present, which confirms the partial effect of dNM. A similar pattern was noted with Endo F, which cleaves also biantennary structures in addition to high-mannose chains. Endo FNG completely deglycosylated d+rgp160 as d-rgpl60, even in the absence of denaturing agents, showing that possible modifications of conformation resulting from dNM treatment did not alter the accessibility of glycosylation sites to the enzyme. Two other recombinant glycoproteins were also investigated as controls: baculovirus-expressed rgp 160 was chosen as representative of a high-mannose-type glycosylated molecule (Morikawa et al., 1990b) , and bacterial rgpl20 as a non°glycosylated molecule (Morikawa et al., 1990a) . Baculovirus rgpl60 appeared more sensitive than d+rgpl60 to Endo H or to Endo F, but was not completely deglycosylated by Endo H as expected. This may be explained by the presence of some highmannose-type glycans that may be resistant to the enzyme (Jarvis & Summers, 1989). However, using rgpl20 produced in a drosophila cell line, we could obtain complete deglycosylation of the molecule by Endo H, indicating efficacy of the enzyme (data not shown).
As described for other glycoproteins, abnormal glycosylation can affect the conformation of env glycoproteins, which may result in altered bioactivity. Concern-ing HIV-I glycoproteins, Fennie & Lasky (1989) have shown that neither dNM nor deoxymannojirimycin impair the CD4-binding activity of rgpl20 produced in mammalian cells, indicating correct functional conformation; somewhat surprisingly, however, Endo Hmediated removal of high-mannose species from normal mature rgpl20 reduced its attachment to CD4, which is at variance with our previous results (Fenouillet et al., 1989 (Fenouillet et al., , 1990 . But in these experiments 1 mM-dNM was applied for only 1 h, the CD4-binding assay used was not quantitative and Endo H treatment was conducted on preformed CD4-gpl20 complexes, and, thus, CD4binding bioactive species of rgpl20 might have been selected. A similar conclusion was drawn from another study in which gpl20-CD4 interaction was examined using a qualitative radioimmunoprecipitation assay (Pal et al., 1989b) . For these reasons, we investigated this point using a quantitative CD4-binding assay already described (Fenouillet et al., 1989 (Fenouillet et al., , 1990 and the whole heterogeneous rgpl60 population produced by dNM o treated cells. Under these conditions significant reduction of d+rgpl60 binding to CD4 + cells was observed. That this was not simply due to an excess of highmannose species present on d+rgp 160 may be inferred by the observation that highly mannosylated baculovirus rgpl60 (Morikawa et al., 1990b) bound perfectly well to the cells. Thus, d+rgpl60 behaved almost like nonglycosylated bacterial gpl20 with respect to CD4binding, which argues that in both cases the bioactive conformation of the molecule was profoundly affected for related reasons. However, and although it is well known that proteins found in E. eoli periplasm possess disulphide bonds (Skerra & Pluckthun, 1988) , other mechanisms that result in incorrect folding may disturb a protein's functional conformation in E. eo/i. Because the major neutralization epitope of HIV-1 is located on the V3 loop, it is thought that this exposed region of gp 120 must play an essential role in the post-CD4-binding events that lead to virus entry into its targets cells (Meloen et al., 1989) . We used MAb 110-4, which recognizes a sequential epitope of the HIV-1 LAV-BRU V3 loop, to examine another possible modification of the molecule conformation which could be of relevance for its biological activity. In both assays used, the avidity of MAb 110-4 for d+rgpl60 in solution was reduced by at least 10-fold as compared with d-rgpl60, which was not the case when rgpl60 was 'distorted after binding' onto a nitrocellulose membrane, an observation that has been reported for other molecules (Parry et al., 1990) . This reduced reactivity was certainly not due to steric hindrance by highly glyclosylated mannosyl-type glycan species because Endo FNG treatment did not increase but rather profoundly reduced d+rgpl60 binding to MAb 110-4 as compared with d-rgpl60. Moreover, baculovirus rgp 160, which contains only high-mannose-type glycans, binds to 110-4 MAb to the same extent as ICC14 rgpl60 does. Therefore, dNM treatment dramatically alters the conformation and accessibility of the V3 loop to antibodies, the recognized epitope being then partially masked for recognition due to the incorrect folding of the molecule.
Taken together, our results indicate that dNM profoundly affects the glycosylation and conformation of rgpl60. This leads to the loss of rgpl60 bioactivity, determined in terms of CD4-binding capability, and to modification of a region, the V3 loop of gpl20, which certainly plays an important role in HIV-1 post-binding events. Modifications to the accessibility of the V3 loop and the conformation of the CD4 binding site together may completely prevent HIV-1 infectivity, in a synergistic manner similarly to MAbs against V3 and the putative CD4 binding site, which together neutralize virus as recently discussed (Tilley et al., 1991) . Although other possible mechanisms such as impaired cleavage of gp 160 into gp41 and gp 120 have not been ruled out in this study, the described modifications alone may account for the impaired HIV-1 infectivity elicited by the drug.
